195 related articles for article (PubMed ID: 21466765)
1. Tumour necrosis factor-α inhibitors are glucocorticoid-sparing in rheumatoid arthritis.
Nilsson AC; Christensen AF; Junker P; Lindegaard HM
Dan Med Bull; 2011 Apr; 58(4):A4257. PubMed ID: 21466765
[TBL] [Abstract][Full Text] [Related]
2. Clinical response, drug survival, and predictors thereof among 548 patients with psoriatic arthritis who switched tumor necrosis factor α inhibitor therapy: results from the Danish Nationwide DANBIO Registry.
Glintborg B; Ostergaard M; Krogh NS; Andersen MD; Tarp U; Loft AG; Lindegaard HM; Holland-Fischer M; Nordin H; Jensen DV; Olsen CH; Hetland ML
Arthritis Rheum; 2013 May; 65(5):1213-23. PubMed ID: 23460467
[TBL] [Abstract][Full Text] [Related]
3. Treatment strategies in patients with rheumatoid arthritis for whom methotrexate monotherapy has failed: data from the NOR-DMARD register.
Lie E; van der Heijde D; Uhlig T; Mikkelsen K; Kalstad S; Kaufmann C; Rødevand E; Kvien TK
Ann Rheum Dis; 2011 Dec; 70(12):2103-10. PubMed ID: 21875874
[TBL] [Abstract][Full Text] [Related]
4. Macrophage migration inhibitory factor polymorphisms do not predict therapeutic response to glucocorticoids or to tumour necrosis factor alpha-neutralising treatments in rheumatoid arthritis.
Radstake TR; Fransen J; Toonen EJ; Coenen MJ; Eijsbouts AE; Donn R; van den Hoogen FH; van Riel PL
Ann Rheum Dis; 2007 Nov; 66(11):1525-30. PubMed ID: 17456524
[TBL] [Abstract][Full Text] [Related]
5. Discontinuation of tumour necrosis factor inhibitors in patients with rheumatoid arthritis in low-disease activity: persistent benefits. Data from the Corrona registry.
Kavanaugh A; Lee SJ; Curtis JR; Greenberg JD; Kremer JM; Soto L; Etzel CJ; Cox V; Yoshida K; Reed GW; Solomon DH
Ann Rheum Dis; 2015 Jun; 74(6):1150-5. PubMed ID: 25471471
[TBL] [Abstract][Full Text] [Related]
6. Herpes Zoster Reactivation in Patients With Rheumatoid Arthritis: Analysis of Disease Characteristics and Disease-Modifying Antirheumatic Drugs.
Pappas DA; Hooper MM; Kremer JM; Reed G; Shan Y; Wenkert D; Greenberg JD; Curtis JR
Arthritis Care Res (Hoboken); 2015 Dec; 67(12):1671-8. PubMed ID: 26018115
[TBL] [Abstract][Full Text] [Related]
7. Glucocorticoid sparing effect of tumour necrosis factor alpha inhibitors in rheumatoid arthritis in real life practice.
Seror R; Dougados M; Gossec L
Clin Exp Rheumatol; 2009; 27(5):807-13. PubMed ID: 19917164
[TBL] [Abstract][Full Text] [Related]
8. Association of brain functional magnetic resonance activity with response to tumor necrosis factor inhibition in rheumatoid arthritis.
Rech J; Hess A; Finzel S; Kreitz S; Sergeeva M; Englbrecht M; Doerfler A; Saake M; Schett G
Arthritis Rheum; 2013 Feb; 65(2):325-33. PubMed ID: 23238986
[TBL] [Abstract][Full Text] [Related]
9. Tolerance and effectiveness of anti-tumor necrosis factor alpha therapies in elderly patients with rheumatoid arthritis: a population-based cohort study.
Genevay S; Finckh A; Ciurea A; Chamot AM; Kyburz D; Gabay C;
Arthritis Rheum; 2007 May; 57(4):679-85. PubMed ID: 17471545
[TBL] [Abstract][Full Text] [Related]
10. Do changes in prescription practice in patients with rheumatoid arthritis treated with biological agents affect treatment response and adherence to therapy? Results from the nationwide Danish DANBIO Registry.
Hetland ML; Lindegaard HM; Hansen A; Pødenphant J; Unkerskov J; Ringsdal VS; Østergaard M; Tarp U
Ann Rheum Dis; 2008 Jul; 67(7):1023-6. PubMed ID: 18272669
[TBL] [Abstract][Full Text] [Related]
11. TNF inhibitor therapy and risk of breast cancer recurrence in patients with rheumatoid arthritis: a nationwide cohort study.
Raaschou P; Frisell T; Askling J;
Ann Rheum Dis; 2015 Dec; 74(12):2137-43. PubMed ID: 25107559
[TBL] [Abstract][Full Text] [Related]
12. Establishment of age- and sex-adjusted reference data for hand bone mass and investigation of hand bone loss in patients with rheumatoid arthritis treated in clinical practice: an observational study from the DANBIO registry and the Copenhagen Osteoarthritis Study.
Ørnbjerg LM; Østergaard M; Jensen T; Hyldstrup L; Bach-Mortensen P; Bøyesen P; Thormann A; Tarp U; Bøhme WP; Lindegaard H; Poulsen UE; Schlemmer A; Graudal N; Rødgaard A; Espesen J; Kollerup GB; Glintborg B; Madsen OR; Jensen DV; Hetland ML
Arthritis Res Ther; 2016 Feb; 18():53. PubMed ID: 26912229
[TBL] [Abstract][Full Text] [Related]
13. Risk of tuberculosis in rheumatoid arthritis patients on tumour necrosis factor-alpha inhibitor treatment in Taiwan.
Ke WM; Chen LS; Parng IM; Chen WW; On AW
Int J Tuberc Lung Dis; 2013 Dec; 17(12):1590-5. PubMed ID: 24200274
[TBL] [Abstract][Full Text] [Related]
14. Low-dose prednisolone in addition to the initial disease-modifying antirheumatic drug in patients with early active rheumatoid arthritis reduces joint destruction and increases the remission rate: a two-year randomized trial.
Svensson B; Boonen A; Albertsson K; van der Heijde D; Keller C; Hafström I
Arthritis Rheum; 2005 Nov; 52(11):3360-70. PubMed ID: 16255010
[TBL] [Abstract][Full Text] [Related]
15. Impact of tumour necrosis factor inhibitor treatment on radiographic progression in rheumatoid arthritis patients in clinical practice: results from the nationwide Danish DANBIO registry.
Ornbjerg LM; Ostergaard M; Bøyesen P; Krogh NS; Thormann A; Tarp U; Poulsen UE; Espesen J; Ringsdal VS; Graudal N; Kollerup G; Jensen DV; Madsen OR; Glintborg B; Christensen T; Lindegaard H; Dencker D; Hansen A; Andersen AR; Hetland ML
Ann Rheum Dis; 2013 Jan; 72(1):57-63. PubMed ID: 22532636
[TBL] [Abstract][Full Text] [Related]
16. One-Year Tuberculosis Risk in Rheumatoid Arthritis Patients Starting Their First Tumor Necrosis Factor Inhibitor Therapy from 2008 to 2012 in Taiwan: A Nationwide Population-Based Cohort Study.
Lim CH; Lin CH; Chen DY; Chen YM; Chao WC; Liao TL; Chen HH
PLoS One; 2016; 11(11):e0166339. PubMed ID: 27832150
[TBL] [Abstract][Full Text] [Related]
17. Incidence and risk factors for serious infection in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors: a report from the Registry of Japanese Rheumatoid Arthritis Patients for Longterm Safety.
Komano Y; Tanaka M; Nanki T; Koike R; Sakai R; Kameda H; Nakajima A; Saito K; Takeno M; Atsumi T; Tohma S; Ito S; Tamura N; Fujii T; Sawada T; Ida H; Hashiramoto A; Koike T; Ishigatsubo Y; Eguchi K; Tanaka Y; Takeuchi T; Miyasaka N; Harigai M;
J Rheumatol; 2011 Jul; 38(7):1258-64. PubMed ID: 21498482
[TBL] [Abstract][Full Text] [Related]
18. Initial disease modifying antirheumatic drugs and prednisolone prescriptions for patients with rheumatoid arthritis: a 15-year study.
Osiri M; Akkasilpa S; Deesomchok U
J Med Assoc Thai; 2000 Mar; 83(3):217-24. PubMed ID: 10808674
[TBL] [Abstract][Full Text] [Related]
19. Real-world evaluation of TNF-inhibitor utilization in rheumatoid arthritis.
Harnett J; Wiederkehr D; Gerber R; Gruben D; Koenig A; Bourret J
J Med Econ; 2016; 19(2):91-102. PubMed ID: 26401963
[TBL] [Abstract][Full Text] [Related]
20. Utilization trends of tumor necrosis factor inhibitors among patients with rheumatoid arthritis in a United States observational cohort study.
Lee SJ; Chang H; Yazici Y; Greenberg JD; Kremer JM; Kavanaugh A
J Rheumatol; 2009 Aug; 36(8):1611-7. PubMed ID: 19369454
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
